What are the indications and dosages for propranolol (beta-blocker) use?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Indications and Dosages for Propranolol

Propranolol is indicated for hypertension, angina pectoris, migraine prophylaxis, and hypertrophic subaortic stenosis, with dosages tailored to each condition. 1

FDA-Approved Indications

  • Hypertension: Initial dose 80 mg once daily (extended-release), may increase to 120-160 mg once daily for maintenance. In some cases, doses up to 640 mg may be required 1
  • Angina Pectoris: Start with 80 mg once daily (extended-release), gradually increase at 3-7 day intervals to optimal response (typically 160 mg daily). Maximum recommended dose is 320 mg daily 1
  • Migraine Prophylaxis: Initial dose 80 mg once daily (extended-release), with effective dose range of 160-240 mg once daily 1
  • Hypertrophic Subaortic Stenosis: Usual dosage is 80-160 mg once daily (extended-release) 1

Additional Clinical Uses

  • Infantile Hemangioma: FDA-approved for pediatric use at 3.4 mg/kg/day, with 60% success rate in complete or nearly complete resolution 2
  • Post-Myocardial Infarction: Used for secondary prevention of cardiovascular events, showing relative risk reduction of 0.73 (95% CI 0.56-0.94) 2
  • Cardiac Arrhythmias: Used for stable narrow-complex tachycardias when other treatments fail 2

Dosing Considerations

  • Immediate-Release Formulation: Typically dosed 2-3 times daily due to shorter half-life 3
  • Extended-Release Formulation: Once-daily dosing provides sustained beta-blockade throughout 24 hours with 30-50% less bioavailability than immediate-release 3
  • Initiation: Start with lower doses and gradually increase to minimize risk of adverse effects 1
  • Discontinuation: Taper gradually over several weeks to avoid rebound hypertension or tachycardia 2, 4

Special Populations

Pediatric Patients (Infantile Hemangioma)

  • Initial dose 1 mg/kg/day, with escalation to target dose of 1-3 mg/kg/day 2
  • Consider inpatient initiation for infants ≤8 weeks, preterm infants, or those with cardiac/pulmonary risk factors 2
  • Duration of therapy typically 3-12 months, until 8-12 months of age 2

Patients with Comorbidities

  • More cautious dosing required for patients with comorbidities that increase hypoglycemia risk 2
  • For segmental infantile hemangiomas (suspected PHACES syndrome), start with 0.5 mg/kg/day 2

Contraindications

  • Sinus bradycardia or heart rate outside normal range for age 2, 4
  • Heart block greater than first-degree 2
  • Cardiogenic shock or heart failure 2
  • Hypotension 2
  • Reactive airways disease or asthma 2, 4
  • Hypoglycemic episodes (recent or ongoing) 2
  • Hypersensitivity to propranolol 2

Monitoring and Safety

  • Cardiovascular examination recommended before starting treatment 2, 4
  • Monitor for hypotension and bradycardia, especially during initiation 4
  • Avoid abrupt discontinuation to prevent rebound hypertension or tachycardia 2, 4
  • May mask symptoms of hypoglycemia in susceptible patients 4
  • For infantile hemangioma treatment, administer propranolol and feed children at intervals not exceeding 8 hours (6 hours in younger infants) to reduce hypoglycemia risk 2

Clinical Pearls

  • In angina pectoris, higher doses (500-800 mg/day) may be required for optimal effect in severe cases, but should be approached gradually 5
  • For hypertension, propranolol is typically used as a second-step drug in combination with a thiazide diuretic when diuretic therapy alone is insufficient 6
  • Can be safely used concurrently with antidepressants without attenuating the therapeutic effects of the antidepressant 7
  • Dental considerations: patients should continue propranolol during dental procedures, but limit use of adrenergic vasoconstrictors 8

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Medication Transition from Flupentixol/Melitracen to Propranolol

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Propranolol in the treatment of angina: a review.

Postgraduate medical journal, 1976

Research

Hypertensive response to levonordefrin in a patient receiving propranolol: report of case.

Journal of the American Dental Association (1939), 1988

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.